Oncoinvent Presents Preliminary 18-Month Safety and Efficacy Data from Ongoing RAD-18-002 Phase 1/2A Trial of Radspherin® in
Colorectal Cancer
Patients at the 13th PSOGI International Congress on
Peritoneal Surface Malignancies

2023-10-04
临床结果放射疗法ASCO会议
At 18 months, no patients at the recommended dose of 7 MBq experienced peritoneal recurrences Robust safety pro no serious adverse events related to Radspherin® reported Presentation on October 4, 2023, at 11:55 a.m. CET (5:55 a.m. EDT) OSLO, Norway--(BUSINESS WIRE)-- Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of
solid cancers
, today announced the presentation of preliminary 18-month safety and efficacy data from its ongoing Phase 1/2A clinical trial evaluating the safety, tolerability, and signal of efficacy of Radspherin® in patients with
peritoneal carcinomatosis
from
colorectal cancer
at the 13th International Congress on Peritoneal Surface Malignancies of the Peritoneal Surface Oncology Group International (PSOGI), to be held at the Palazzo del Cinema in Venice, Italy from October 4 - 6, 2023. The presentation, titled “18-month safety and efficacy after intraperitoneal treatment with 224Radium-labelled microparticles (Radspherin) after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) for
colorectal peritoneal metastasis (PM)
” will be presented on October 4, 2023 from 11:55 a.m. to 12:05 p.m. CET (5:55 a.m. EDT). “We are thrilled to continue to demonstrate the robust safety and efficacy pro Radspherin® with the presentation of 18-month data at PSOGI. At 18 months, none of the patients administered Radspherin® at the recommended dose experienced peritoneal recurrences. Along with a demonstrated robust safety profile, we believe Radspherin® has potential as a novel treatment,” said Anders Månsson, Chief Executive Officer of Oncoinvent. “These data represent a significant clinical milestone for Radspherin®, giving us confidence in its potential to prevent peritoneal recurrence. We look forward to the continued clinical development of this promising therapy.” Details of the oral presentations are as follows: Oral Presentation Session: Session II Oral Abstract –
Colorectal Cancer
Presentation Title: 18-month safety and efficacy after intraperitoneal treatment with 224Radium-labelled microparticles (Radspherin) after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) for
colorectal peritoneal metastasis (PM)
Presenting Author: Stein Gunnar Larsen, MD, PhD, Oslo University Hospital, the Norwegian Radium Hospital. Oral Presentation Date and Time: October 4th, 2023, from 11:55 a.m. to 12:05 p.m. CET (5:55 a.m. EDT). This Phase 1/2A study is designed to evaluate the safety, tolerability, and signal of efficacy of Radspherin® injected intraperitoneally two days after the completion of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). A dose of 7 MBq was recommended following the completion of dose escalation 1-2-4-7 MBq. A total of 23 patients with peritoneal metastasis from
colorectal cancer
were enrolled, with 12 receiving the recommended dose of 7MBq. Preliminary safety and survival data at 18-months is presented. Key results: At 18 months, none of the 12 patients who received the recommended dose of 7 MBq experienced peritoneal recurrences Only 2.6% of all adverse events reported were considered to be related to Radspherin®, all of which were grade 1-2 Additionally, a poster demonstrating Radspherin® as a novel radiopharmaceutical for treatment for peritoneal metastasis will be presented on October 4th, 2023 Poster Presentation Session: Treatment and Prevention of
Peritoneal Metastases
from
Colorectal Cancer
Poster Title: Novel radiopharmaceutical for intraperitoneal treatment of peritoneal metastasis from colorectal and ovarian cancer after complete surgical resection Presenting Author: Kari Myren, Oncoinvent AS Poster Presentation Date and Time: October 4th, 2023, from 1:00 p.m. to 1:30 p.m. CET (7:00 a.m. to 7:30 a.m. EDT) About Oncoinvent Oncoinvent AS is a clinical stage company developing innovative radiopharmaceutical technology that delivers precise, alpha-emitting particles across
solid cancers
. By leveraging internal manufacturing and supply chain capabilities to enable a clinical supply of radioisotopes, the company is advancing a pipeline of novel products that use alpha particles, a higher Linear Energy Transfer (LET) form of radiation, that can potentially eradicate
cancer
cells. Oncoinvent’s lead candidate, Radspherin®, is designed for treatment of
metastatic cancers
in body cavities, and its versatility allows it to be deployed for the treatment of a variety of
cancer
indications. Radspherin® is in two ongoing clinical studies to treat
peritoneal carcinomatosis
from both
ovarian cancer
and
colorectal cancer
. View source version on businesswire.com: Contacts Source: Oncoinvent AS View this news release online at:
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
适应症
结直肠癌,腹膜癌,实体瘤
[+4]
靶点
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。